North China Pharmaceutical Group Co., Ltd. is the largest pharmaceutical enterprise in China, located in Shijiazhuang, the capital of Hebei Province.
North China pharmacy
The company's predecessor, North China Pharmaceutical Factory, was a national key construction project during the First Five-Year Plan period. It consists of an antibiotic factory, a starch factory and a medical glass factory imported from the former Democratic Republic of Germany in the 156 key project aided by the former Soviet Union. Construction started on June 1953, with a total investment of 75.88 million yuan, and was put into operation on June 1958.
The establishment of North China Pharmaceutical Factory initiated the history of large-scale production of antibiotics in China, ended the history of China's dependence on imported penicillin and streptomycin, and the situation of lack of doctors and medicines was obviously improved.
Since its establishment more than 50 years ago, Huayao has been operating steadily, expanding gradually, expanding its business scope, increasing its sales volume and maintaining excellent performance. Its main economic indicators have been in the forefront of the same industry in China. Compared with when it was put into production, its business scope expanded from simple pharmacy to biology, chemicals, pesticides, commerce and other fields, and its main products increased from 5 to more than 430 varieties, and from a factory with a single property right structure to more than 30 subsidiaries, with diversified products.
Shiyan Pharmaceutical Group Co., Ltd., established by Hebei Pharmaceutical Group Corporation and Shijiazhuang No.1 Pharmaceutical Group Corporation on1June 5438+August 2, 9971,is the first super-large pharmaceutical enterprise in the national pharmaceutical industry and one of the large pillar enterprise groups in Hebei Province.
Unacon has total assets of11500 million yuan and employs about 20,000 people. It owns more than ten subsidiaries including Zhongrun Pharmaceutical, Weisheng Pharmaceutical, Zhongnuo Pharmaceutical, Ou Yi Pharmaceutical, Enbipu Pharmaceutical and Xinhui Pharmaceutical, which are located in Hebei, Shanxi, Tianjin, Jilin, Liaoning and Inner Mongolia.
Among them, China Pharmaceutical Group Co., Ltd., a holding subsidiary of Hong Kong, is the first overseas listed company in China's pharmaceutical industry, one of the largest pharmaceutical listed companies in Hong Kong at present, and one of the constituent stocks of Hong Kong Hang Seng Red Chip Index. It has been rated as one of the 65,438+000 outstanding listed companies in Asia with a turnover of less than $6,543.8+billion by the world-famous Forbes magazine for two consecutive times.
In July 2009, China Pharmaceuticals was selected into the list of "Top 20 Most Competitive Pharmaceutical Listed Companies in China".
Younuokang is a super-large pharmaceutical enterprise integrating science, industry and trade, mainly engaged in research and development, production and sales of pharmaceutical products.
The products mainly include six series of antibiotics, vitamins, cardiovascular and cerebrovascular diseases, antipyretic and analgesic diseases, digestive system and respiratory system drugs, with penicillin series and vitamins as the leading products.
At present, the annual production capacity of vitamin C, penicillin series APIs, 7-ACA, amoxicillin and caffeine reaches 35,000 tons, 6,543.8+6,000 tons, respectively, ranking first in the world.
The annual production capacity of Younuokang preparation is 3 billion injections, 20 billion tablets, 8 billion capsules and 654.38+0 billion soft capsules.
The output, scale and strength of Unocal's leading products are among the best in China, and it has developed into one of the largest production bases of chemical raw materials and comprehensive preparations in China.
At present, Unacon has 30 products with sales exceeding 100 million yuan, and the products are sold all over the country and more than 60 countries and regions around the world.
Since its establishment more than ten years ago, Yunakang has made great progress in innovation and endeavor. It has successively won the honorary titles of National Advanced Collective of Pharmaceutical System, Advanced Enterprise of Quality and Benefit, Unit with Assured Commitment of Product Quality, National May 1st Labor Certificate, China Environmental Protection Enterprise Love Award, etc.
In 2009, Unacon's sales revenue excluding tax was 654.38+006 billion yuan, and its profits and taxes were 654.38+046 billion yuan and 654.38+026.548+000 billion yuan respectively, and it paid various taxes of 500 million yuan.
The whole group earned US$ 450 million through direct export, ranking among the top pharmaceutical manufacturers in China.
In terms of scientific research and development, Unocal has developed more than 90 national new drugs in recent years, involving biotechnology, chiral synthetic drugs, liposomes, transdermal preparations, molecular microcapsules and other fields, relying on the enterprise's "postdoctoral research center", national enterprise technology center, "863 Program" high-tech industrialization base, and Hebei Medical Engineering Technology Center.
At present, Unacon * * * has applied for more than 220 patents, of which 1 16 has been authorized, and 17 has applied for PCT international patent.
Among them, Enbip, a national first-class new drug with independent intellectual property rights, is the world's leading drug in the field of stroke treatment, and the third national first-class new drug with independent intellectual property rights in China, filling the historical gap of national first-class new drugs in Hebei Province and obtaining patent protection in 86 countries around the world.
At present, the company has signed an agreement with two well-known companies in the United States and South Korea on the transfer of the patent right of Enbip soft capsules in Europe, America and South Korea, which has created a precedent for China pharmaceutical enterprises to transfer medical intellectual property rights to the most developed countries in the world and won honor for the country and the nation.
In 2008, under the leadership of the Ministry of Science and Technology and with the support of the National Science and Technology Support Program, China Antibiotic Industry Technology Innovation Alliance was established.
In the national science and technology major special declaration of "major new drug creation", 1 innovative drug incubation base, 3 innovative drug R&D technology platforms and 6 new drug R&D projects have settled in Shi Yao, becoming the enterprises that have received the most support from policy projects in the industry.
In terms of product quality, Unocal has established a complete three-level quality management system, all drugs have passed GMP certification, and all subordinate enterprises have passed ISO9000, OHSAS 18000, ISO 1400 1 certification, and the product market inspection qualification rate has always remained at 100%.
At the same time, the company enhances the quality connotation with technology. At present, eight APIs, such as caffeine, vitamin C, VB 12 and amoxicillin, have obtained the COS certification of the European Union and obtained the "passport" to enter the high-end pharmaceutical market in Europe and America.
In terms of brand building, Unacon owns two well-known trademarks in China: "Shi Yao" and "Ou Yi". According to the evaluation of World Brand Lab, one of the top five brand value evaluation agencies in the world, Shi Yao brand has been selected as "China 500 Most Valuable Brands" for four consecutive times since 2005. Unikon has been selected as one of the top 500 Chinese enterprises for three times in a row, and was shortlisted for the 2008 China Most Brand Value Enterprise Award. In 2008, it was a leading enterprise in the manufacturing of chemical drugs and APIs in China.
Looking forward to the future, Shi Yao people will continue to adhere to the corporate philosophy of "making good drugs for China", devote themselves to the cause of human health, contribute more, newer and better drugs to the society, and strive to build Unocal into a first-class modern large-scale pharmaceutical enterprise in China and one of the top 500 in the world.